Tirzepatide

Discovery and Structure

Tirzepatide is a dual agonist of the GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, developed by Eli Lilly and first disclosed in 2016 as compound LY3298176. It is a 39-amino-acid synthetic peptide built on a modified exendin-4 backbone and lipidated with a C20 fatty-diacid side chain that binds serum albumin, giving it a half-life of roughly 5 days and enabling once-weekly subcutaneous dosing.

Its defining design feature is engineered dual receptor activity: tirzepatide binds the GIP receptor with near-native affinity and the GLP-1 receptor with somewhat lower affinity than native GLP-1. That imbalance is deliberate — GIP activation appears to amplify the metabolic effects of GLP-1 signaling while also mitigating GLP-1-associated nausea, at least at the doses studied.

Mechanism of Action

Single-molecule activation of two incretin receptors produces effects that neither GLP-1 alone nor GIP alone achieves:

• Synergistic insulin response. GLP-1 and GIP are the two dominant incretin hormones; activating both glucose-dependently enhances postprandial insulin secretion more than monotherapy at either receptor.
• Glucagon suppression and delayed gastric emptying. Shared with pure GLP-1 agonists like semaglutide.
• Adipose tissue signaling. GIP receptors are highly expressed on adipocytes; GIP agonism appears to improve lipid handling and insulin sensitivity in fat tissue, possibly explaining the larger weight-loss magnitude seen with tirzepatide compared to pure GLP-1 agents.

Clinical Evidence

Tirzepatide's Phase 3 program ran in two parallel streams. The SURPASS trials (5 studies) evaluated glycemic control in type 2 diabetes, with tirzepatide producing HbA1c reductions of up to ~2.5 percentage points — larger than any comparator including semaglutide 1 mg in head-to-head SURPASS-2. The SURMOUNT trials evaluated weight management. SURMOUNT-1 (2022) reported mean weight loss of roughly 20.9% at the 15 mg dose over 72 weeks in adults with obesity without diabetes — a magnitude approaching bariatric-surgery territory. SURMOUNT-2 extended the indication to obesity with type 2 diabetes, and SURMOUNT-3 demonstrated additional weight loss after lifestyle run-in.

The cardiovascular outcomes trial SURPASS-CVOT reported non-inferiority to dulaglutide on major adverse cardiovascular events in 2024, and SUMMIT (2024) showed benefit in heart failure with preserved ejection fraction in patients with obesity.

Regulatory History

The FDA approved tirzepatide as Mounjaro for type 2 diabetes in May 2022, and as Zepbound for chronic weight management in November 2023. European Medicines Agency approval followed. A sleep-apnea indication — the first pharmacological therapy approved specifically for obstructive sleep apnea tied to obesity — was added to the Zepbound label in December 2024 based on the SURMOUNT-OSA trial.

Safety and Practical Considerations

Adverse-event profiles mirror the GLP-1 class: nausea, diarrhea, vomiting, and constipation are most common, concentrated during titration, and typically improve over weeks. Pancreatitis and gallbladder disease have been reported. The label carries the same boxed warning for rodent thyroid C-cell tumors as semaglutide, with the same contraindications in MEN2 syndrome and personal or family history of medullary thyroid carcinoma.

Clinically, tirzepatide is typically titrated from 2.5 mg weekly upward in 4-week increments to a maintenance dose (5, 10, or 15 mg). Compounded versions proliferated during the 2023–2024 shortage period; the FDA has progressively restricted compounding since the shortage resolved.

The Bottom Line

Tirzepatide represents the most effective single-agent pharmacotherapy for obesity and diabetes approved to date, and it validated the multi-agonist thesis that now dominates late-stage pipelines. For a structured comparison with semaglutide and the triple-agonist retatrutide, see our 2026 head-to-head analysis.